10q10k10q10k.net
PTC THERAPEUTICS, INC.

PTC THERAPEUTICS, INC.PTCTEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Top Holders

Holder% OwnedSharesChangeAs of
The Vanguard Group11.66%
8.8M
—2024-02-13
Wellington Management Group LLP10.26%
7.9M
▼ -2.75pp2024-11-08
BlackRock, Inc.10.20%
7.7M
—2024-01-08
RTW Investments, LP9.80%
7.4M
—2024-02-14
Armistice Capital, LLC9.40%
7.2M
▲ +0.30pp2024-11-14
Camber Capital5.31%
4.0M
—2023-10-30
STATE STREET CORPORATION3.80%
2.9M
▼ -2.34pp2024-10-18
FMR LLC2.40%
1.8M
▼ -6.12pp2024-01-10

Insider Transactions

Net 90d: −$8.63M · buys $0 / sells $8.63M
Range:
Action:
Role:
InsiderRoleAction
2026-04-21Klein Matthew B.CHIEF EXECUTIVE OFFICERSell (open market)
2.9K
$70.91$202.1K
2026-04-06Boulding Mark ElliottEXEC. VP AND CLOOption exercise
2.3K
$39.42$89.3K
2026-04-06Boulding Mark ElliottEXEC. VP AND CLOSell (open market)
822
$68.91$56.6K
2026-04-06Boulding Mark ElliottEXEC. VP AND CLOSell (open market)
1.4K
$69.75$100.6K
2026-04-02Golden Lee ScottEVP & CHIEF MEDICAL OFFICERSell (open market)
829
$67.99$56.4K
2026-04-01Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSell (open market)
39.4K
$68.89$2.71M
2026-04-01Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSell (open market)
12.5K
$69.50$870.8K
2026-04-01Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSell (open market)
80
$70.30$5.6K
2026-03-24Chutter Jessica CarolineDirectorGrant
4.0K
$0.00$0
2026-03-24Chutter Jessica CarolineDirectorGrant
3.3K
$0.00$0
1–10 of 34
Page 1 / 4